Sheila Brown, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 5213 High Vista Dr, Orefield, PA 18069 Phone: 610-366-8086 |
News Archive
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Aptilon Corporation, a leader in online access, engagement and interaction with physicians and healthcare professionals on behalf of pharmaceutical and life sciences companies, today announced its financial results for the year ended December 31, 2010.
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.
Learning disabilities such as dyslexia are believed to affect nearly one in 10 children. To better study them, a Northwestern University research team has developed a data-driven conceptual framework that links two well-established scientific concepts. In doing so, they also have developed a non-invasive diagnostic tool called BioMAP that can quickly identify children with learning disabilities.
The number of cancer survivors in the United States increased to 11.7 million in 2007, according to a report the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) released today. This is a nearly 20 percent increase in cancer survivors from 2001.
› Verified 9 days ago